Major alterations to U.S. vaccination policies under Robert F. Kennedy Jr. have raised concerns about accessibility and coverage of new vaccines, potentially affecting public health for years to come.
In a significant shift in U.S. vaccination policy, Robert F. Kennedy Jr., the Secretary of the U.S. Department of Health and Human Services (HHS), has implemented sweeping changes that have left the future of vaccine recommendations in limbo. This uncertainty, stemming from cuts to childhood immunization recommendations and the replacement of experts on the Advisory Committee on Immunization Practices (ACIP), has resulted in widespread concerns regarding vaccine access and public health. Experts warn that the repercussions of these changes could persist for years.
Kennedy’s administration has reportedly reduced childhood vaccination recommendations by one-third and has appointed individuals aligned with his views to the ACIP, which is responsible for advising on immunization practices. A recent court ruling has temporarily halted these changes, citing procedural issues. However, Kennedy has yet to nominate new members to the committee, stalling any new vaccination recommendations even as new vaccines receive approval.
One such vaccine is the new Moderna mRNA flu vaccine, which was approved by the U.S. Food and Drug Administration (FDA) in August for individuals aged 50 and older. According to reports, this vaccine is suggested to offer enhanced protection compared to traditional flu shots. Ron Kroening, a 63-year-old with asthma and severe allergies, faced difficulties accessing the new vaccine, eventually locating the sole pharmacy in his area that carried it. To his surprise, he was charged a $40 co-pay, a cost he had never experienced for a flu shot before.
“I figured that was an error because I’ve never had to pay for a flu shot in my life,” Kroening recounted. His insurance company informed him that the lack of an ACIP recommendation was the reason for the co-pay. Kroening expressed concern that such costs could deter individuals from getting vaccinated, particularly given his background as a retired public health employee who had worked on immunization efforts in Oklahoma. “This is really a barrier. And any barrier to immunizations is going to keep people from getting them,” he added.
Impact of ACIP Recommendations on Insurance Coverage
Typically, insurance companies have at least one year following FDA approval to incorporate coverage for a new vaccine into their plans. However, the current situation is complicated by the uncertainty surrounding ACIP recommendations. If the committee does not recommend the new flu vaccine by the end of the year, insurers may not be required to cover it until January 2029, at the earliest.
Lindsay Wiley, a professor of law and faculty director of the Health Law and Policy Program at UCLA Law, explained that the legal requirements for insurance coverage take time to enact. She noted that for the new flu shot, it is probable that a recommendation may not be made until next year, yet there are no guarantees. “It’s just delaying more and more and more,” Wiley stated.
Moreover, the uncertainty surrounding ACIP has broader implications. In some states, pharmacists are not permitted to administer vaccines without an ACIP recommendation. Prior decisions made by the committee prior to its disbandment have also been impacted. For instance, a recommendation on new shots to prevent respiratory syncytial virus (RSV) that was set for September 2025 has been put on hold, although insurers appear to be covering them regardless. Additionally, a vote to end the universal birth dose of the hepatitis B vaccine has raised concerns about potential changes to state-level vaccination laws.
Delays have also been reported regarding Medicare coverage for the new flu shots for seniors, despite federal mandates that typically ensure coverage independent of ACIP recommendations.
Political Ramifications and Future of ACIP
The U.S. government has appealed the court ruling that effectively disbanded the vaccine committee. However, experts argue that there is nothing preventing Kennedy from proceeding with the correct process for appointing new ACIP members, which he has not yet done. Aaron Siri, who has represented Kennedy and litigated against vaccine manufacturers, criticized the current administration for failing to reinstate the vaccine committee, suggesting that it appears the Department of Justice and the White House are deliberately stalling its functionality.
Dorit Reiss, a vaccines expert at UC Law San Francisco, echoed this sentiment, noting that the federal government has opted not to establish a new ACIP. She remarked on the lack of expertise displayed by Kennedy’s appointees during public meetings, calling it “embarrassing” even for anti-vaccine activists. Reiss indicated that there are strategic advantages for Kennedy in delaying the reconstitution of the ACIP, as it allows him to make recommendations without committee oversight. She also stressed that the undermining of trust in ACIP’s independence could have long-term consequences for its future.
Concerns Among Insurers and Public Health
Despite the challenges, Kroening’s insurer is a member of the insurance industry group AHIP, which has committed to covering all vaccines recommended as of September 2025. Insurers retain the option to cover vaccines prior to the mandated timeline. Kroening expressed his frustration with the current situation, stating, “They’re harder to get now. It’s a mess right now, what they’re doing with our vaccines.” While he plans to continue receiving the new vaccine, he remains concerned about the broader implications for immunization accessibility in the United States.
As the political landscape around vaccination policy continues to evolve, the future of immunization practices in the U.S. remains uncertain. The ongoing developments are likely to have lasting effects on public health, insurance coverage, and the trust in advisory committees responsible for maintaining vaccination standards.
No Comment! Be the first one.